POLYPEPTIDE GROUP AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29 CHF | -4.29% |
|
-2.36% | +65.53% |
| 12/03 | PolyPeptide Group AG Provides Earnings Guidance for 2024 | CI |
| 12/03 | Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024 |
ETFs positioned on PolyPeptide Group AG
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +1.32% | - | |
| 0.00% | 152 M€ | -2.89% | - | |
| 0.00% | 26 M€ | -4.26% | - |
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Sector
Pharmaceuticals
Calendar
13/08/2024
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
30.91
EUR
Average target price
22.24
EUR
Spread / Average Target
-28.07%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +65.53% | 1.09B | |
| +31.09% | 699B | |
| +25.07% | 571B | |
| -4.68% | 364B | |
| +18.11% | 326B | |
| +2.65% | 286B | |
| +14.68% | 236B | |
| +4.71% | 198B | |
| -12.43% | 194B | |
| -4.45% | 154B |
- Stock Market
- Equities
- PPGN Stock
- Funds and ETFs PolyPeptide Group AG
